Australia's most trusted
source of pharma news
Posted December 7, 2021 PM
AstraZeneca is the latest big pharma said to be considering carving off part of its business into a separate entity, with the company's newly formed COVID-19 vaccine and antibody treatment unit tipped as ripe to spin out on its own.
Just last month the company set up the new division which would take control of the company's vaccine Vaxzevrvia and its long acting antibody Evusheld as well as several other respiratory infection treatments.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.